Investor Presentation

24X Ongoing Phase 3 RESOLVE-1 Study 52 Week study Topline data expected 2020 Double-blind, randomized, placebo-controlled study Multinational ÎÒÅÒÂÎÄÎÎ ~354 subjects Lenabasum 20mg BID 5mg BID Placebo 1:1:1 dosing Primary Endpoint: Change from baseline in mRSS Secondary Endpoints: Change from baseline in HAQ-DI; ACR CRISS; Change from baseline in FVC % predicted

View entire presentation